Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction

Link to article at PubMed

Cardiol Clin. 2022 Nov;40(4):533-540. doi: 10.1016/j.ccl.2022.06.007. Epub 2022 Sep 15.


Heart failure with preserved ejection fraction (HFpEF) is a common medical condition associated with increased morbidity and mortality. Through different mechanisms, including passive left-sided congestion and/or vasculopathy, patients with HFpEF can develop pulmonary hypertension (PH). This association -PH-HFpEF- is linked with worsening symptomatology and long-term outcomes. Although pulmonary vasodilators have been effective in treating patients with a pulmonary vasculopathy, such as pulmonary arterial hypertension (PAH), these results have not been replicated in those with PH-HFpEF. There is an unmet need to develop effective medical therapy for this challenging population. In this article, we focus on understanding the definition, epidemiology, diagnosis, clinical implications, and treatment for PH in the setting of HFpEF.

PMID:36210136 | DOI:10.1016/j.ccl.2022.06.007

Leave a Reply

Your email address will not be published. Required fields are marked *